옵션 체인은 다양한 행사가격과 만기일에 대한 AZEK Co의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 AZEK Co에 대한 시장 심리를 평가합니다..

AZEK Co (NYSE:AZEK) 주식, 옵션 체인

AZEK CO INC/THE

AZEK Co

The AZEK Co Inc is a designer and manufacturer of beautiful, low maintenance and environmentally sustainable products focused on the fast-growing Outdoor Living market. Its portfolio of products includes decks, rail, trim, outdoor furniture among others. The company operates in two segments: Residential Segment that manufactures and distributes decking, railing, trim, moulding, pergolas and cabanas and accessories through a national network of dealers and distributors and multiple home improvement retailers; and Commercial Segment that manufactures, fabricates and distributes lockers and bathroom partitions. It generates maximum revenue from the Residential segment. The company's brand includes TimberTech; AZEK; Versatex, Ultralox, StruXure, and Intex.

electric vehicle shutter3

Analyst Color

Long Ideas

Markets

Analyst Ratings

Trading Ideas

AZEK

EVGO

PLUG

지속 가능한 투자가 2025년으로 향하는 엇갈린 신호에 직면함에 따라 일부 주식은 ESG 촉매제의 혜택을 받을 수 있는 좋은 위치에 있다. 2024년에 광범위한 지속가능 펀드가 시장 대비 저조한 성과를 보였지만, 녹색 성장 트렌드를 활용하는 주식에는 여전히 기회가 존재한다.

플러그 파워와 EV고는 JP모건의 2025년 지속 가능한 최고 투자 종목 중 하나

Wall-Street-ai7-1

Earnings

Equities

Large Cap

Mid Cap

Tech

ETFs

AMGN

AVGO

DELL

Janus Henderson Group plc Ordinary Shares

KVYO

MNDY

NVDA

QGEN

SNOW

TOST

UPST

3분기 실적 시즌이 다가오면서, 골드만삭스는 투자자들이 재무 실적을 통해 수익을 올릴 수 있는 주요 주식 기회를 식별한 노트를 발표했다. 애널리스트 존 마샬(John Marshall)과 그의 팀은 목요일에 18개의 주식이 실적 상향 조정의 혜택을 받을 가능성이 있고, 7개의 주식은 하향 조정의 영향을 받을 가능성이 있다고 강조했다.

이번 실적 시즌에 매수할 주식 18개, 매도할 주식 7개: 골드만삭스는 올해를 &#39;주식 선택자의 해&#39;

The AZEK Company Inc. Class A Common Stock

The AZEK Co Inc

<p>B of A Securities  analyst Sara Senatore   maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Buy and raises the price target from $319 to $360.</p>


News

Price Target

WING

B of A Securities Maintains Buy on Wingstop, Raises Price Target to $360

<p><strong>Banzai International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-15. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Banzai International will report an <strong>earnings per share</strong> (EPS) of $-4.00. </p>
<p>The market awaits Banzai International's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS beat by $7.85 in the last quarter, leading to a 13.11% drop in the share price on the following day.</p>
<p>Here's a look at Banzai International's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-8</td>
<td>-4.50</td>
<td>-6.5</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.15</td>
<td>-0.46</td>
<td>-7.5</td>
<td>-13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-13.0%</td>
<td>-11.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Tracking Banzai International's Stock Performance</h3>
<p>Shares of Banzai International were trading at $0.9993 as of May 13. Over the last 52-week period, shares are down 93.42%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BNZI/earnings"><strong>To track all earnings releases for Banzai International visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BNZI

Earnings Outlook For Banzai International

<p>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) will release its quarterly earnings report on Thursday, 2025-05-15. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Expion360 to report an <strong>earnings per share</strong> (EPS) of $-0.64.</p>
<p>The announcement from Expion360 is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS missed by $0.12 in the last quarter, leading to a 2.65% drop in the share price on the following day.</p>
<p>Here's a look at Expion360's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0</td>
<td></td>
<td>-0.003</td>
<td>-0.003</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.12</td>
<td>-24.55</td>
<td>-0.003</td>
<td>-0.003</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>-25.0%</td>
<td>2.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Stock Performance</h3>
<p>Shares of Expion360 were trading at $1.05 as of May 13. Over the last 52-week period, shares are down 99.5%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/XPON/earnings"><strong>To track all earnings releases for Expion360 visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


XPON

Insights into Expion360's Upcoming Earnings

<p>Wells Fargo  analyst Ike Boruchow   maintains Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) with a Equal-Weight and raises the price target from $171 to $187.</p>


Wells Fargo Maintains Equal-Weight on Dick's Sporting Goods, Raises Price Target to $187

<p>Sensus Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-15. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Sensus Healthcare to report an <strong>earnings per share</strong> (EPS) of $0.12.</p>
<p>The market awaits Sensus Healthcare's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.03, leading to a 32.37% drop in the share price the following trading session.</p>
<p>Here's a look at Sensus Healthcare's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.12</td>
<td>-0.01</td>
<td>0.02</td>
<td>-0.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.09</td>
<td>0.07</td>
<td>0.10</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-32.0%</td>
<td>5.0%</td>
<td>1.0%</td>
<td>39.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747231349_0.png" alt="eps graph" /></p>
<h3>Tracking Sensus Healthcare's Stock Performance</h3>
<p>Shares of Sensus Healthcare were trading at $4.59 as of May 13. Over the last 52-week period, shares are down 29.75%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analysts' Perspectives on Sensus Healthcare</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Sensus Healthcare.</p>
<p>With 2 analyst ratings, Sensus Healthcare has a consensus rating of Buy. The average one-year price target is $12.5, indicating a potential 172.33% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of  and Sensus Healthcare, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for  and Sensus Healthcare are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensus Healthcare</td>
<td>Buy</td>
<td>3.97%</td>
<td>$7.11M</td>
<td>2.81%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Sensus Healthcare ranks in the middle among peers for Consensus rating. It is at the bottom for Revenue Growth, indicating lower growth compared to peers. The company is at the top for Gross Profit, reflecting strong profitability. However, it ranks at the bottom for Return on Equity, suggesting lower returns generated on shareholders' equity.</p>
<h3>All You Need to Know About Sensus Healthcare</h3>
<p>Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.</p>
<h3>Sensus Healthcare's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Sensus Healthcare's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>3.97%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Sensus Healthcare's net margin is impressive, surpassing industry averages. With a net margin of <strong>11.83%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Sensus Healthcare's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>2.81%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Sensus Healthcare's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.53%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.01</strong>.</p>
<p><a href="https://www.benzinga.com/quote/SRTS/earnings"><strong>To track all earnings releases for Sensus Healthcare visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SRTS

Exploring Sensus Healthcare's Earnings Expectations

<p>Shares of <strong>Palantir Technologies Inc.&nbsp;</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) are trending higher Wednesday. The stock has been in a strong uptrend since it reversed after heading lower despite a <a href="https://www.benzinga.com/news/25/05/45383727/palantir-stock-hits-new-all-time-high-on-strong-earnings-macro-tailwinds">good earnings report</a>.</p>
<p>We have made it our Stock of the Day. It appears to be breaking out, and this is typically a bullish dynamic which would suggest further moves upwards.</p>
<p>The price action in Palantir after it released its earnings was confusing to many traders and investors. The numbers were ahead of estimates but the stock sold off. It was a classic case of ‘buy the rumor, sell the news.&#8217;</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="549" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085349/one8-1024x549.png" alt="" class="wp-image-914976" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085349/one8-1024x549.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085349/one8-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085349/one8-768x412.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085349/one8.png 1507w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>Wall Street widely anticipated a strong earnings report. Traders expected the report to be a catalyst for higher prices.</p>
<p>Because of this, they took positions and bought shares before the earnings were released. So, when the news hit the tape, the market had run out of buyers.</p>
<p><strong>Read Also:</strong> <a href="https://www.benzinga.com/25/05/45389449/4-tech-stocks-with-huge-earnings-momentum">4 Tech Stocks With Huge Earnings Momentum</a></p>
<p>And if no one is left to buy, the price can only move lower.</p>
<p>Now the stock appears to have broken resistance. This can be a bullish dynamic.</p>
<p>Resistance is a price level or zone where there is a large amount of sell interest or shares for sale.</p>
<p>If a stock is moving higher, there are more shares to be bought than there are to be sold. People who wish to buy are forced to outbid each other to draw sellers into the market. This could force the shares into an uptrend.</p>
<p>When stocks reach resistance, rallies end or pause.</p>
<p>Sometimes stock sell off of resistance. This happened to Palantir when it reached $124.00 early this month.</p>
<p>But sometimes when a stock reaches resistance, the buyers eventually overpower the sellers and the resistance ‘breaks.' This is bullish because if the shares are trading at a higher level than the resistance, it shows that the investors and traders who created the resistance have left the market.</p>
<p>They have finished or canceled their orders.</p>
<p>With this large amount of support taken off of the market, buyers will need to be aggressive and outbid each other again if they wish to acquire shares. This could set the stage for a continued move higher in Palantir.</p>
<p><strong>Read Next:</strong> </p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/bonds/25/05/45396490/peter-schiff-says-trade-truce-aside-the-world-is-losing-confidence-in-dollar-and-in-us-ability-to-put-fiscal-house-in-order"><strong>Peter Schiff Says Trade Truce Aside, The World Is &#8216;Losing Confidence&#8217; In Dollar And In US Ability To Put &#8216;Fiscal House In Order&#8217;</strong></a></li>
</ul>



Technicals

Topics

PLTR

Stock Of The Day: Palantir Breaks Out As Classic 'Sell the News' Sets Up Rally

<p>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) will release its quarterly earnings report on Thursday, 2025-05-15. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Omeros to report an <strong>earnings per share</strong> (EPS) of $-0.60.</p>
<p>Investors in Omeros are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company beat EPS by $0.08, leading to a 3.77% drop in the share price the following trading session.</p>
<p>Here's a look at Omeros's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.71</td>
<td>-0.70</td>
<td>-0.69</td>
<td>-0.58</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.63</td>
<td>-0.64</td>
<td>-0.97</td>
<td>-0.63</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>66.0%</td>
<td>-6.0%</td>
<td>-21.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747231339_0.png" alt="eps graph" /></p>
<h3>Market Performance of Omeros's Stock</h3>
<p>Shares of Omeros were trading at $4.43 as of May 13. Over the last 52-week period, shares are up 27.19%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/OMER/earnings"><strong>To track all earnings releases for Omeros visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


OMER

Examining the Future: Omeros's Earnings Outlook

<p>Tariffs have skyrocketed. Supply chains are tangled. Small businesses are bracing themselves. But amid the economic friction, a surprising gesture from China may have cracked open the door to compromise.&nbsp;</p>
<p>On April 17, hedge fund billionaire <strong>Bill Ackman </strong>reacted to Beijing&#8217;s proposal for a 90-day pause on its own tariffs, calling the development a hopeful sign: &#8220;The rift is healing,&#8221; he<a href="https://x.com/BillAckman/status/1911402888389157233"> posted on X</a>. Ackman&#8217;s comment followed China&#8217;s call for the U.S. to drop its additional trade levies after Washington made a move to exempt certain electronics from tariffs.</p>
<p><strong>Don't Miss:</strong></p>
<ul class="wp-block-list">
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</strong></a></strong></li>
<li><strong>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"><strong> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</strong></a>.</strong></li>
</ul>
<h2 class="wp-block-heading">Ackman Wants A Pause To Prevent Business Fallout</h2>
<p>The trade war has escalated in recent months. The Trump administration steadily raised tariffs on Chinese imports, reaching a peak of 145% in early April. In return, China imposed retaliatory tariffs at 125% on U.S. goods, triggering disruptions across sectors on both sides of the Pacific.&nbsp;</p>
<p>According to<a href="https://www.reuters.com/world/trump-we-will-have-trade-deal-with-china-2025-04-17/"> Reuters</a>, the Chinese Ministry of Commerce urged the U.S. to fully eliminate the tariffs and resume talks grounded in &#8220;mutual respect.&#8221;</p>
<p>Ackman, founder of Pershing Square Capital Management, weighed in on April 13 <a href="https://x.com/BillAckman/status/1911381955641213023">via an X post</a>.&nbsp;</p>
<p>&#8220;If President Trump were to pause the China tariffs for 90 days and reduce them temporarily to 10%, he would achieve the same objective in causing US businesses to relocate their supply chains from China without the disruption and risk to these businesses in the short term,&#8221; he wrote.&nbsp;</p>
<p><strong>Trending: How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"><strong> </strong><strong>Tax deferring is their number one strategy</strong></a>.</strong></p>
<p>This, Ackman explained, would give U.S. small and medium-sized businesses a breather to adjust their supply chains without immediate financial fallout.</p>
<p>He also clarified that such a move wouldn&#8217;t signal weakness. &#8220;The result has been nations lining up to negotiate deals with the administration,&#8221; he wrote. That means such a move would boost the U.S.&#8217;s negotiating power and if the tariffs are reframed as a strategic pause.</p>
<p>These comments come days after Trump exempted key electronics and semiconductor items from new reciprocal tariffs. According to Ackman, that exemption triggered China&#8217;s response—and now created an opening for real negotiations.</p>
<p>Meanwhile, the effects of the trade war are becoming increasingly visible. Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) 737 Max <a href="https://www.theguardian.com/us-news/2025/apr/21/china-returns-boeing-737-jet-us-too-expensive-tariffs">jetliner</a> originally purchased by China&#8217;s Xiamen Airlines was returned to the U.S. on April 20 due to mounting import costs.&nbsp;</p>
<p><strong><em>See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel"><strong><em>Invest before it's too late.</em></strong></a></em></strong></p>
<p>In a separate move, Hongkong Post <a href="https://www.info.gov.hk/gia/general/202502/05/P2025020500487p.htm">announced </a>that it had suspended all package delivery services to the U.S., citing tariff-related costs.</p>
<p>China&#8217;s export data also shows movement. According to the<a href="https://apnews.com/article/china-trade-economy-tariffs-exports-86ecd3f1594b69e537085ae94e8f0e8f"> Associated Press</a>, Chinese exports surged 12.4% in March as manufacturers rushed shipments ahead of the harsher U.S. tariff schedules.&nbsp;</p>
<p>Despite the spike, economists warn that both countries may face slower growth in the months ahead. On April 16, <a href="https://www.reuters.com/world/china/view-chinas-q1-economic-growth-beats-estimates-trade-tensions-cloud-outlook-2025-04-16/">Reuters reported</a> that China&#8217;s first-quarter GDP outlook is dimming due to escalating trade tensions and weakening domestic demand.&nbsp;&nbsp;</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123"><strong>Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</strong></a></strong></li>
<li><strong>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.30/share with a $1000 minimum.</strong></a></strong></li>
</ul>
<p><em><strong>Image: Midjourney</strong></em></p>


Personal Finance

Bill Ackman Says 'The Rift Is Healing' As China Opens Door To 90-Day Tariff Pause, Urges Trump To Lower Levies To 10%

<p><strong>Bit Digital</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-15. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Bit Digital will report an <strong>earnings per share</strong> (EPS) of $-0.07. </p>
<p>Investors in Bit Digital are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.23, leading to a 0.0% drop in the share price on the subsequent day.</p>
<p>Here's a look at Bit Digital's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.03</td>
<td>-0.02</td>
<td>-0.03</td>
<td>0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.20</td>
<td>-0.26</td>
<td>-0.09</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>7.000000000000001%</td>
<td>0.0%</td>
<td>21.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747231329_0.png" alt="eps graph" /></p>
<h3>Market Performance of Bit Digital's Stock</h3>
<p>Shares of Bit Digital were trading at $2.24 as of May 13. Over the last 52-week period, shares are down 2.4%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Insights Shared by Analysts on Bit Digital</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Bit Digital.</p>
<p>With 2 analyst ratings, Bit Digital has a consensus rating of Buy. The average one-year price target is $7.0, indicating a potential 212.5% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Cerence, Ooma and Kaltura, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Cerence, with an average 1-year price target of $10.4, suggesting a potential 364.29% upside.</li>
<li>Analysts currently favor an Buy trajectory for Ooma, with an average 1-year price target of $18.5, suggesting a potential 725.89% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Kaltura, with an average 1-year price target of $3.67, suggesting a potential 63.84% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Cerence, Ooma and Kaltura, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bit Digital</td>
<td>Buy</td>
<td>409.63%</td>
<td>$66.22M</td>
<td>7.62%</td>
</tr>
<tr>
<td>Cerence</td>
<td>Neutral</td>
<td>53.27%</td>
<td>$33.07M</td>
<td>16.04%</td>
</tr>
<tr>
<td>Ooma</td>
<td>Buy</td>
<td>5.55%</td>
<td>$39.93M</td>
<td>-0.31%</td>
</tr>
<tr>
<td>Kaltura</td>
<td>Outperform</td>
<td>4.92%</td>
<td>$32.74M</td>
<td>-4.76%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Bit Digital ranks highest in Revenue Growth among its peers. It is at the bottom in Gross Profit and Return on Equity.</p>
<h3>All You Need to Know About Bit Digital</h3>
<p>Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.</p>
<h3>Key Indicators: Bit Digital's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Bit Digital's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>409.63%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>35.41%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Bit Digital's ROE excels beyond industry benchmarks, reaching <strong>7.62%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Bit Digital's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.34%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.03</strong>, Bit Digital adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/BTBT/earnings"><strong>To track all earnings releases for Bit Digital visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BTBT

Earnings Preview: Bit Digital

<p>Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on the company's PK activators, mitapivat and tebapivat, will be featured in oral and poster presentations during the 30th European Hematology Association (EHA) Congress (EHA 2025) in Milan, Italy, June 12-15, 2025.</p>


AGIO

Agios Pharma: New Data On PK Activators, Mitapivat And Tebapivat, To Be Featured In Oral And Poster Presentations During EHA Congress 2025

<p><strong>KULR Tech Gr</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-15. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that KULR Tech Gr will report an <strong>earnings per share</strong> (EPS) of $-0.01. </p>
<p>The announcement from KULR Tech Gr is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS missed by $0.00 in the last quarter, leading to a 0.0% drop in the share price on the following day.</p>
<p>Here's a look at KULR Tech Gr's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.02</td>
<td>-0.02</td>
<td>-0.02</td>
<td>-0.03</td>
<td>-0.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.02</td>
<td>-0.01</td>
<td>-0.03</td>
<td>-0.04</td>
<td>-0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>-23.0%</td>
<td>-18.0%</td>
<td>-21.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747231319_0.png" alt="eps graph" /></p>
<h3>Tracking KULR Tech Gr's Stock Performance</h3>
<p>Shares of KULR Tech Gr were trading at $1.57 as of May 13. Over the last 52-week period, shares are up 352.7%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Insights Shared by Analysts on KULR Tech Gr</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on KULR Tech Gr.</p>
<p>The consensus rating for KULR Tech Gr is Buy, based on 1 analyst ratings. With an average one-year price target of $5.0, there's a potential 218.47% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Amprius Technologies, ChargePoint Hldgs and LSI Industries, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Amprius Technologies, with an average 1-year price target of $9.25, suggesting a potential 489.17% upside.</li>
<li>Analysts currently favor an Neutral trajectory for ChargePoint Hldgs, with an average 1-year price target of $0.78, suggesting a potential 50.32% downside.</li>
<li>Analysts currently favor an Buy trajectory for LSI Industries, with an average 1-year price target of $26.0, suggesting a potential 1556.05% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for Amprius Technologies, ChargePoint Hldgs and LSI Industries are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>KULR Tech Gr</td>
<td>Buy</td>
<td>44.42%</td>
<td>$2.14M</td>
<td>-14.76%</td>
</tr>
<tr>
<td>Amprius Technologies</td>
<td>Buy</td>
<td>383.05%</td>
<td>$-2.36M</td>
<td>-13.40%</td>
</tr>
<tr>
<td>ChargePoint Hldgs</td>
<td>Neutral</td>
<td>-12.04%</td>
<td>$28.70M</td>
<td>-36.93%</td>
</tr>
<tr>
<td>LSI Industries</td>
<td>Buy</td>
<td>22.46%</td>
<td>$32.84M</td>
<td>1.77%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>KULR Tech Gr ranks at the bottom for Revenue Growth and Gross Profit, while it ranks at the top for Return on Equity among its peers. The Consensus rating for KULR Tech Gr is the same as one of its peers.</p>
<h3>All You Need to Know About KULR Tech Gr</h3>
<p>KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.</p>
<h3>Unraveling the Financial Story of KULR Tech Gr</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> KULR Tech Gr displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>44.42%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> KULR Tech Gr's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-137.08%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> KULR Tech Gr's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-14.76%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> KULR Tech Gr's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-12.28%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> KULR Tech Gr's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.03</strong>.</p>
<p><a href="https://www.benzinga.com/quote/KULR/earnings"><strong>To track all earnings releases for KULR Tech Gr visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


KULR

KULR Tech Gr Earnings Preview

<p><strong>Canadian Solar</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-15. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Canadian Solar will report an <strong>earnings per share</strong> (EPS) of $-0.69. </p>
<p>The announcement from Canadian Solar is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS missed by $1.23 in the last quarter, leading to a 1.84% increase in the share price on the following day.</p>
<p>Here's a look at Canadian Solar's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.24</td>
<td>-0.12</td>
<td>0.13</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.47</td>
<td>-0.31</td>
<td>0.02</td>
<td>0.19</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>5.0%</td>
<td>10.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747231307_0.png" alt="eps graph" /></p>
<h3>Market Performance of Canadian Solar's Stock</h3>
<p>Shares of Canadian Solar were trading at $10.15 as of May 13. Over the last 52-week period, shares are down 35.8%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analysts' Take on Canadian Solar</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Canadian Solar.</p>
<p>The consensus rating for Canadian Solar is Neutral, derived from 2 analyst ratings. An average one-year price target of $8.5 implies a potential 16.26% downside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Alpha &amp; Omega, Wolfspeed and CEVA, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Alpha &amp; Omega, with an average 1-year price target of $25.0, suggesting a potential 146.31% upside.</li>
<li>Analysts currently favor an Buy trajectory for Wolfspeed, with an average 1-year price target of $5.67, suggesting a potential 44.14% downside.</li>
<li>Analysts currently favor an Buy trajectory for CEVA, with an average 1-year price target of $38.83, suggesting a potential 282.56% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for Alpha &amp; Omega, Wolfspeed and CEVA are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canadian Solar</td>
<td>Neutral</td>
<td>-10.62%</td>
<td>$217.04M</td>
<td>1.19%</td>
</tr>
<tr>
<td>Alpha &amp; Omega</td>
<td>Buy</td>
<td>9.71%</td>
<td>$35.18M</td>
<td>-1.21%</td>
</tr>
<tr>
<td>Wolfspeed</td>
<td>Buy</td>
<td>-13.39%</td>
<td>$-37.20M</td>
<td>-74.33%</td>
</tr>
<tr>
<td>CEVA</td>
<td>Buy</td>
<td>9.85%</td>
<td>$20.76M</td>
<td>-1.24%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Canadian Solar is positioned in the middle compared to its peers in terms of consensus rating. It ranks at the bottom for revenue growth among its peers. In gross profit, it is at the top among the group. However, for return on equity, Canadian Solar is placed in the middle compared to its peers.</p>
<h3>Discovering Canadian Solar: A Closer Look</h3>
<p>Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.</p>
<h3>Financial Milestones: Canadian Solar's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Canadian Solar's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-10.62%</strong>. This indicates a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Canadian Solar's net margin is impressive, surpassing industry averages. With a net margin of <strong>2.23%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Canadian Solar's ROE excels beyond industry benchmarks, reaching <strong>1.19%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.25%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Canadian Solar's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.1</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/CSIQ/earnings"><strong>To track all earnings releases for Canadian Solar visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CSIQ

A Glimpse of Canadian Solar's Earnings Potential

<p>Kyocera (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KYOCY#OTC">KYOCY</a>) reported quarterly earnings of $0.03 per share. This is a 46 percent decrease over earnings of $0.05 per share from the same period last year.  The company reported $3.42 billion in sales this quarter. This is a 0.64 percent decrease over sales of $3.45 billion the same period last year.</p>


KYOCY

Kyocera Q4 EPS $0.03 Down From $0.05 YoY, Sales $3.42B Down From $3.45B YoY

<p>– Ziftomenib combined with 7+3 in 1L <i>NPM1</i>-m or <i>KMT2A</i>-r AML patients selected for oral presentation on Thursday, June 12th –</p>
<p>– Updated dataset to be presented in oral presentation at EHA2025 Congress –</p>
<p>SAN DIEGO and TOKYO, May 14, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>, "Kura"))) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced that an abstract highlighting clinical data from the KOMET-007 combination trial of ziftomenib, a once-daily, oral investigational menin inhibitor, has been accepted for presentation at the upcoming 2025 European Hematology Association (EHA) Congress, to be held in Milan, Italy, from June 12-15, 2025.</p>
<p>KOMET-007 is a multicenter Phase 1 trial of ziftomenib in combination with standards of care, including cytarabine plus daunorubicin (7+3) and venetoclax/azacitidine (ven/aza), in patients with <i>NPM1</i>-mutant (<i>NPM1</i>-m) and <i>KMT2A</i>-rearranged (<i>KMT2A</i>-r) acute myeloid leukemia (AML). The data presented at EHA will be from the Phase 1a dose-escalation and Phase 1b dose-expansion portions of the trial, in the cohort evaluating ziftomenib in combination with 7+3 in newly diagnosed patients with AML.</p>


Biotech

General

KURA

Kura Oncology And Kyowa Kirin Announce Combination Data For Ziftomenib In Oral Presentation At The 2025 EHA Congress

WIIM

RIVN

Rivian Automotive shares are trading lower after Jefferies downgraded the stock from Buy to Hold.

<p>KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) is preparing to release its quarterly earnings on Thursday, 2025-04-17. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect KeyCorp to report an <strong>earnings per share</strong> (EPS) of $0.32.</p>
<p>The market awaits KeyCorp's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.06 in the last quarter, leading to a 1.93% drop in the share price on the following day.</p>
<p>Here's a look at KeyCorp's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.32</td>
<td>0.32</td>
<td>0.15</td>
<td>0.24</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.33</td>
<td>0.38</td>
<td>0.30</td>
<td>0.25</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-2.0%</td>
<td>1.0%</td>
<td>0.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747231289_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of KeyCorp were trading at $16.62 as of May 13. Over the last 52-week period, shares are up 8.28%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/KEY/earnings"><strong>To track all earnings releases for KeyCorp visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview: KeyCorp

<p>Cantor Fitzgerald  analyst Ross Osborn   reiterates NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) with a Overweight and maintains $17 price target.</p>


Reiteration

NPCE

Cantor Fitzgerald Reiterates Overweight on NeuroPace, Maintains $17 Price Target

<p>15 analysts have shared their evaluations of UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for UnitedHealth Group, revealing an average target of $530.47, a high estimate of $660.00, and a low estimate of $350.00. Observing a downward trend, the current average is 14.01% lower than the prior average price target of $616.87. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747231281_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of UnitedHealth Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$350.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$356.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$450.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$510.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$513.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$525.00</td>
<td>$652.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$525.00</td>
<td>$655.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$563.00</td>
<td>$664.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$580.00</td>
<td>$660.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$560.00</td>
<td>$642.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$575.00</td>
<td>$650.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$540.00</td>
<td>$635.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$600.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$660.00</td>
<td>$610.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$650.00</td>
<td>$600.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UnitedHealth Group. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of UnitedHealth Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of UnitedHealth Group's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UNH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on UnitedHealth Group analyst ratings.</strong></a></p>
<h2>About UnitedHealth Group</h2>
<p>UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.</p>
<h3>Financial Insights: UnitedHealth Group</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> UnitedHealth Group's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>9.8%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>5.74%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>6.7%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> UnitedHealth Group's ROA excels beyond industry benchmarks, reaching <strong>2.07%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> UnitedHealth Group's debt-to-equity ratio is below the industry average at <strong>0.86</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where UnitedHealth Group Stands With Analysts

<p>VEON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-15. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect VEON to report an <strong>earnings per share</strong> (EPS) of $0.83.</p>
<p>Anticipation surrounds VEON's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company beat EPS by $0.21, which was followed by a 2.03% increase in the share price the next day.</p>
<p>Here's a look at VEON's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.77</td>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.98</td>
<td>3</td>
<td>0.04</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-2.0%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Tracking VEON's Stock Performance</h3>
<p>Shares of VEON were trading at $51.25 as of May 13. Over the last 52-week period, shares are up 95.92%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/VEON/earnings"><strong>To track all earnings releases for VEON visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


VEON

Earnings Outlook For VEON

<p>Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) will release its quarterly earnings report on Thursday, 2025-05-15. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Globant to report an <strong>earnings per share</strong> (EPS) of $1.59.</p>
<p>The announcement from Globant is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company beat EPS by $0.01, which was followed by a 27.81% drop in the share price the next day.</p>
<p>Here's a look at Globant's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.74</td>
<td>1.63</td>
<td>1.50</td>
<td>1.53</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.75</td>
<td>1.63</td>
<td>1.51</td>
<td>1.53</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-28.000000000000004%</td>
<td>-11.0%</td>
<td>5.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747231272_0.png" alt="eps graph" /></p>
<h3>Performance of Globant Shares</h3>
<p>Shares of Globant were trading at $140.36 as of May 13. Over the last 52-week period, shares are down 22.99%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Opinions on Globant</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Globant.</p>
<p>A total of 11 analyst ratings have been received for Globant, with the consensus rating being Outperform. The average one-year price target stands at $192.36, suggesting a potential 37.05% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of DXC Technology, ASGN and EPAM Systems, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for DXC Technology, with an average 1-year price target of $16.0, suggesting a potential 88.6% downside.</li>
<li>Analysts currently favor an Buy trajectory for ASGN, with an average 1-year price target of $61.33, suggesting a potential 56.31% downside.</li>
<li>Analysts currently favor an Outperform trajectory for EPAM Systems, with an average 1-year price target of $218.86, suggesting a potential 55.93% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for DXC Technology, ASGN and EPAM Systems, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Globant</td>
<td>Outperform</td>
<td>10.64%</td>
<td>$229.32M</td>
<td>1.88%</td>
</tr>
<tr>
<td>DXC Technology</td>
<td>Neutral</td>
<td>-5.12%</td>
<td>$809M</td>
<td>1.91%</td>
</tr>
<tr>
<td>ASGN</td>
<td>Buy</td>
<td>-7.69%</td>
<td>$275.40M</td>
<td>1.17%</td>
</tr>
<tr>
<td>EPAM Systems</td>
<td>Outperform</td>
<td>11.69%</td>
<td>$349.68M</td>
<td>2.02%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Globant ranks highest in Revenue Growth and Gross Profit among its peers. It also has the highest Return on Equity.</p>
<h3>Delving into Globant's Background</h3>
<p>Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.</p>
<h3>Globant: A Financial Overview</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Globant showcased positive performance, achieving a revenue growth rate of <strong>10.64%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Globant's net margin is impressive, surpassing industry averages. With a net margin of <strong>5.64%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.88%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Globant's ROA excels beyond industry benchmarks, reaching <strong>1.19%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Globant's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.21</strong>.</p>
<p><a href="https://www.benzinga.com/quote/GLOB/earnings"><strong>To track all earnings releases for Globant visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GLOB

An Overview of Globant's Earnings

Press Releases

AZEK INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AZEK Company Inc. - AZEK

Comments

AZEK Co

AZEK Co (AZEK) 옵션

AZEK Co (NYSE:AZEK) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌